Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma?
We discuss all that and more on a special live (to tape) episode “The Readout LOUD,” STAT’s biotech podcast. In front of a studio audience in Boston, we talk about the first glimpse at how genome editing affects actual humans and the disappointment it brought. Then we take a look at how 2018 has panned out for some of biotech’s hot-button issues, including buyouts, IPOs, and President Trump’s effect on drug prices. We also dive into former Celgene CEO Bob Hugin’s effort to win a Senate race in New Jersey at a time when his industry is widely disliked. And then we embark upon live lightning round, answering questions from members of the audience.
What is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports